Jean-Pierre Latere, EsoBiotec CEO

As­traZeneca to buy cell ther­a­py start­up for $425M up­front

As­traZeneca said Mon­day that it has agreed to ac­quire a cell ther­a­py biotech found­ed just four years ago for an up­front pay­ment of $425 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.